BMY
Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 70.46$. Average daily volumn in 3 months 8.25M. Market cap 143.23B
Stock symbol : BMY. Exchange : NYSE. Currency : USD Lastest price : 68.10$. Total volume : 2.46M. Market state REGULAR Click reload if you want to check the lastest price on market!!!
Bristol-Myers Squibb Company (BMY)
Last Price
68.10$Change
0.03Volume
2.46M
| Previous Close | 68.07 |
| Open | 68.08 |
| Day Range | 67.96-68.59 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1.2k |
| Volume | 2.46M |
| Average Volume | 8.25M |
| Market Cap | 143.23B |
| Beta | 0.45 |
| 52 Week Range | 65.28-81.44 |
| Trailing P/E | 23.08 |
| Foward P/E | 8.29 |
| Dividend (Yield %) | 3.35% |
| Ex-Dividend Date | 2023-01-05 |
Financial Details
Organization
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myelom... a; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Market Cap:
143.23BRevenue:
46.16BTotal Assets:
96.82BTotal Cash:
9.12B
News about "Bristol-Myers Squibb Company"
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
Source from : YAHOO!Finance - 15 hours ago
The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programmes.See details»
Should You Invest in Bristol-Myers Squibb Company (BMY) Now?
Source from : newsheater - 7 days ago
Bristol-Myers Squibb Company (NYSE: BMY) has a higher price-to-earnings ratio of 22.78x compared to its average ratio,, and the 36-month beta value for BMY is at 0.44. Analysts have varying views on ...See details»
Bristol-Myers Squibb: Growth Story And Valuation Is Convincing
Source from : Seeking Alpha - 2 days ago
Despite dealing with a pharmaceutical company, Bristol-Myers Squibb's performance during recessions was mixed and the stock also performed horrible in the last two decades. For fiscal 2022 ...See details»
Bristol Myers Squibb Company
Source from : BN Americas - 2 years ago
Company: Processing Solutions Inc. Company: Citibank Latin America Citibank Latin America is the regional unit of multinational financial services company Citibank. The regional division was ...See details»
Bristol-Myers Squibb Company (BMY) Shares Down Despite Recent Market Volatility
Source from : newsheater - 25 days ago
Bristol-Myers Squibb Company (NYSE: BMY)’s stock price has decreased by -0.56 compared to its previous closing price of 67.48. However, the company has experienced a 0.89% gain in its stock price over ...See details»
Bristol-Myers Squibb Company (NYSE:BMY) insiders sold US$39m worth of stock suggesting impending weakness.
Source from : Yahoo - 26 days ago
Many Bristol-Myers Squibb Company (NYSE:BMY) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions ...See details»
With 78% ownership of the shares, Bristol-Myers Squibb Company (NYSE:BMY) is heavily dominated by institutional owners
Source from : Yahoo - 1 month ago
Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable to their trading decisions A total of 25 investors have a majority stake in the company ...See details»
Bristol-Myers Squibb Company (NYSE: BMY) Down -0.67%: This Is What Analysts Are Now Forecasting
Source from : stocksregister - 12 days ago
Bristol-Myers Squibb Company (NYSE:BMY) price on Thursday, March 16, fall -0.67% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $67.03. A look at the ...See details»
Bristol Myers Squibb (BMY) Stock Moves -0.4%: What You Should Know
Source from : Zacks.com on MSN - 6 days ago
Bristol Myers Squibb (BMY) closed at $67.24 in the latest trading session, marking a -0.4% move from the prior day. This move was narrower than the S&P 500's daily loss of 1.65%. At the same time, the ...See details»
Bristol Myers Squibb Co. stock outperforms market on strong trading day
Source from : MarketWatch - 13 days ago
Shares of Bristol Myers Squibb Co. advanced 1.52% to $67.48 Wednesday, on what proved to be an all-around grim trading session for the stock market, with ...See details»
Bristol Myers Squibb Co.
Source from : Wall Street Journal - 15 days ago
1 Day BMY 0.44% DJIA -0.28% S&P 500 -0.15% Health Care/Life Sciences -0.58% Giovanni Caforio Chairman & Chief Executive Officer Stryker Corp., Bristol Myers Squibb Co., European Federation of ...See details»
Bristol-Myers Squibb (NYSE:BMY) Seems To Use Debt Quite Sensibly
Source from : Yahoo Finance - 5 days ago
So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We can see that Bristol-Myers Squibb ...See details»
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity Commitments
Source from : Stockhouse - 13 days ago
Bristol Myers Squibb. As part of the company's health disparity commitments, the additional nearly $10 million in health equity grants will be dispersed among 17 U.S. nonprofit organizations in 2023.See details»
Bristol Myers wins dismissal of a $6.4 billion lawsuit over cancer drug delay
Source from : Yahoo News - 27 days ago
NEW YORK (Reuters) -A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers Squibb Co of defrauding investors who ... The New York-based company won FDA approval for Breyanzi on Feb. 5, ...See details»